MagForce
Market Cap
€128.0m
Last Updated
2019/10/23 21:01 UTC
Data Sources
Company Financials +
Executive Summary
MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland.
Snowflake
Fundamentals
Exceptional growth potential and good value.
Share Price & News
How has MagForce's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
11.3%
MF6
4.2%
DE Medical Equipment
1.7%
DE Market
1 Year Return
-22.8%
MF6
22.1%
DE Medical Equipment
7.2%
DE Market
Return vs Industry: MF6 underperformed the German Medical Equipment industry which returned 22.1% over the past year.
Return vs Market: MF6 underperformed the German Market which returned 7.2% over the past year.
Shareholder returns
| MF6 | Industry | Market | |
|---|---|---|---|
| 7 Day | 11.3% | 4.2% | 1.7% |
| 30 Day | 4.0% | 2.9% | 2.4% |
| 90 Day | -6.1% | 1.4% | 2.3% |
| 1 Year | -22.8%-22.8% | 24.1%22.1% | 10.6%7.2% |
| 3 Year | 8.7%8.7% | 113.3%107.7% | 18.4%8.1% |
| 5 Year | -14.3%-14.3% | 292.1%272.3% | 42.3%22.9% |
Price Volatility Vs. Market
How volatile is MagForce's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is MagForce undervalued compared to its fair value and its price relative to the market?
48.9%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MF6 (€4.63) is trading below our estimate of fair value (€9.07)
Significantly Below Fair Value: MF6 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MF6 is good value based on its PE Ratio (28.1x) compared to the Medical Equipment industry average (33.3x).
PE vs Market: MF6 is poor value based on its PE Ratio (28.1x) compared to the German market (19x).
Price to Earnings Growth Ratio
PEG Ratio: MF6 is good value based on its PEG Ratio (0.5x)
Price to Book Ratio
PB vs Industry: MF6 is overvalued based on its PB Ratio (6.7x) compared to the DE Medical Equipment industry average (5.9x).
Next Steps
Future Growth
How is MagForce forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
57.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MF6's forecast earnings growth (57.3% per year) is above the savings rate (0.2%).
Earnings vs Market: MF6's earnings (57.3% per year) are forecast to grow faster than the German market (12.7% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MF6's revenue (56.1% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: MF6's revenue (56.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MF6's Return on Equity is forecast to be very high in 3 years time (46.9%).
Next Steps
Past Performance
How has MagForce performed over the past 5 years?
-14.7%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: MF6 has become profitable over the past 5 years, growing earnings by -14.7% per year.
Accelerating Growth: MF6 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MF6 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (6.4%).
Return on Equity
High ROE: MF6's Return on Equity (24%) is considered high.
Return on Assets
ROA vs Industry: MF6 has a higher Return on Assets than the Medical Equipment industry average last year.
Return on Capital Employed
ROCE Improving: MF6 is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is MagForce's financial position?
Financial Position Analysis
Short Term Liabilities: MF6's short term assets (€2.6M) exceeds its short term liabilities (€1.7M)
Long Term Liabilities: MF6's short term assets (2.6M) do not cover its long term liabilities (17.3M)
Debt to Equity History and Analysis
Debt Level: MF6's debt to equity ratio (87.4%) is considered high
Reducing Debt: Insufficient data to determine if MF6's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: Insufficient data to determine if MF6's debt is well covered by operating cash flow.
Interest Coverage: Insufficient data to determine if MF6's interest payments on its debt are well covered by EBIT.
Balance Sheet
Inventory Level: MF6 has a low level of unsold assets or inventory.
Debt Coverage by Assets: MF6's debt is not covered by short term assets (assets are 0.2x debt).
Next Steps
Dividend
What is MagForce's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate MF6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MF6's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if MF6's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MF6's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MF6's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
What is the CEO of MagForce's salary, the management and board of directors tenure and is there insider trading?
7.0yrs
Average management tenure
CEO
Ben Lipps (79yo)
6.1yrs
Tenure
Dr. Benjamin J. Lipps, also known as Ben, has been the Chairman of the Management Board and Chief Executive Officer at MagForce AG since September 1, 2013. Dr. Lipps served as the Chief Executive Officer a ...
Management Age and Tenure
7.0yrs
Average Tenure
62yo
Average Age
Experienced Management: MF6's management team is seasoned and experienced (7 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Andreas Jordan (60yo)
Founder & Advisor
- Tenure: 0yrs
Ben Lipps (79yo)
Chairman of the Management Board & CEO
- Tenure: 6.1yrs
Christian Von Volkmann (48yo)
CFO & Member of Management Board
- Tenure: 7yrs
Hans Hutt
Medical Consultant
- Tenure: 8.9yrs
Solveig Salomon
VP of Marketing & Sales and European Commercial Director
- Tenure: 0yrs
Barbara Frankenberg
Vice President of Communications & Investor Relations
- Tenure: 3.6yrs
Hoda Tawfik (64yo)
Chief Medical Officer & Member of Management Board
- Tenure: 7yrs
Board Members
Norbert Neef (52yo)
Chairman of the Supervisory Board
- Tenure: 0yrs
Wiebke Rösler
Member of the Supervisory Board
- Tenure: 5.2yrs
Klemens Hallmann (43yo)
Deputy Chairman of Supervisory Board
- Tenure: 2.2yrs
Company Information
MagForce AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: MagForce AG
- Ticker: MF6
- Exchange: XTRA
- Founded: 1997
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €127.974m
- Shares outstanding: 27.64m
- Website: https://www.magforce.com
Number of Employees
Location
- MagForce AG
- Max-Planck-Strasse 3
- Berlin
- Berlin
- 12489
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MF6 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Sep 2007 |
| MF6 | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Sep 2007 |
| MGFR.F | OTCPK (Pink Sheets LLC) | Yes | Common Stock | US | USD | Sep 2007 |
| 0W10 | LSE (London Stock Exchange) | Yes | Common Stock | GB | EUR | Sep 2007 |
Biography
MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland. It offers NanoTherm therapy for the treatment of solid tumors; NanoTherm, a ferrofluid liquid containing su ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/23 21:01 |
| End of Day Share Price | 2019/10/23 00:00 |
| Earnings | 2018/12/31 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.